Bipartisan backlash against PBMs grows as critics target vertical integration by chains

Sep 28

Written By Jonathan Karush

Jonathan Karush

4 largest PBMs control 75% of U.S. market, AMA finds

PBM formulary exclusions top 600 drugs amid pricing shift